
Alpha Profiles · Company Profile
ALUMIS INC.
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders.
https://registry.alpha.ac/companies/alumis-inc
- Entity
- Public listing published
- Primary listing
- NASDAQ: ALMS
- Verification
- Partially verified
- Last reviewed
- 2026-09-13T04:46:01.80734+00:00
Overview
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibo
Source record
Alpha canonical company public projection
Supports Company identity, Published leadership, Entity status boundary
Reviewed 2026-09-13T04:46:01.80734+00:00
